确诊后第二次监测活检时MRI在前列腺癌主动监测中的表现
在Canary主动监测队列中,101例有既往MRI知情活检与103例无既往MRI知情活检的GG1前列腺癌患者,在第二次监测活检时比较重分类率。结论支持第二次活检时使用MRI,但阴性MRI不应替代活检。
要点
- MRI阴性预测值在有既往MRI组为87%(95%CI 78-96),无既往组为73%(95%CI 61-85)。
- 无论有无既往MRI,第二次活检均应同时取靶向与系统穿刺。
核心结论
- 结果支持在第二次监测活检时使用MRI,但阴性监测MRI不应替代第二次活检。
研究设计与样本
- Canary前列腺主动监测研究中的前瞻性队列分析,纳入Gleason分级分组1患者,有既往MRI知情活检101例、无既往MRI知情活检103例。
主要发现
- 多变量模型中,第二次监测活检时PI-RADS 4或5病变与重分类风险增加相关(OR=2.04,95%CI 1.04-4.05)。
- MRI阴性预测值在有既往MRI组为87%(95%CI 78-96),无既往组为73%(95%CI 61-85)。
临床怎么用
- 在第二次监测活检时进行MRI检查。
- 即使监测MRI为阴性,仍应进行第二次活检。
- 无论有无既往MRI知情活检,第二次活检均应同时取靶向穿刺和系统穿刺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No clear guidelines exist regarding MRI use after confirmatory biopsy during active surveillance. Our objective was to evaluate MRI performance after confirmatory biopsy in patients with vs without prior MRI-informed biopsy. MATERIALS AND METHODS: Patients in the Canary Prostate Active Surveillance Study with Gleason Grade Group (GG) 1 disease undergoing MRI-informed Biopsy 2, defined as second surveillance biopsy after diagnosis, were separated into prior vs no prior MRI-informed biopsy groups. Primary outcome was reclassification (≥GG2) at MRI-informed Biopsy 2. Reclassification rates and location (systematic cores, targeted cores, both) were compared between groups. Univariable and multivariable logistic regression identified predictors of reclassification. RESULTS: Patients with (n = 101) vs without (n = 103) prior MRI-informed biopsy had lower reclassification rates at Biopsy 2 (21% vs 36%, P = .017) and lower GG at reclassification (95% vs 73% of reclassifications to GG2, P = .039). In multivariable modeling, Prostate Imaging Reporting and Data System 4 or 5 lesion at MRI-informed Biopsy 2 was associated with increased odds of reclassification (odds ratio = 2.04, 95% CI [1.04-4.05]). The negative predictive value of MRI at Biopsy 2 was 87% (95% CI [78-96]) and 73% (95% CI [61-85]) in with vs without prior MRI groups. Reclassification location was identified by targeted cores only in 36% vs 19% of patients with vs without prior MRI (P = .4). Reclassification location was identified by systematic cores only in 36% vs 58% of patients with vs without prior MRI (P = .4). CONCLUSIONS: These results support MRI use at Biopsy 2 and suggest negative surveillance MRI should not replace Biopsy 2. Both targeted and systematic cores should be taken at Biopsy 2 in patients with and without prior MRI on active surveillance.
引用
- Chappidi MR, Newcomb LF, Zheng Y, et al. Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study. J Urol. 2025. PMID: 40305682. doi:10.1097/JU.0000000000004592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。